The KLOW peptide vial: composition, routes, half-lives, and the pharmacokinetic mismatch

In plain English

KLOW peptide is a research-only co-formulation. No validated human dosing exists for the blend. This page describes what the component research literature has established about dosing in preclinical models, what the canonical vial composition looks like, what the four individual components' half-lives suggest about how they behave in the body at different rates, and what that pharmacokinetic mismatch means for interpreting any single co-dosed vial.

This page does not provide dosing recommendations. Nothing here is a personal prescription. Doses described are those administered to specific species in specific research contexts by specific routes — not instructions for human use. For KLOW research into each component's studied doses, context follows.

KLOW peptide dosage: the canonical vial composition

The most widely cited research-vial composition across independent compounders is:

• GHK-Cu: 50 mg (the mass-dominant component, ~62.5% of the vial)
• BPC-157: 10 mg (~12.5%)
• TB-500: 10 mg (~12.5%)
• KPV: 10 mg (~12.5%)
• Total: 80 mg lyophilized powder

The four peptides are co-lyophilized (freeze-dried) at these fixed ratios and supplied as a powder for reconstitution with bacteriostatic water for research handling. They do not form a single molecule — they remain four distinct chemical species in solution.

No pharmacopeial standard, FDA-approved labeling, or clinical protocol specifying a validated dose of the KLOW co-formulation exists. The 80 mg figure is a compounding convention for research vials, not a clinically validated dose.

Copper(II) in GHK-Cu can participate in redox chemistry. Co-dissolving it with three other peptides in one vial raises a theoretical chemical-compatibility and oxidation question that has not been formally characterized for this mixture. Reconstituted solution is typically refrigerated.

KLOW dosage: component-level research doses

Because no dose-ranging study exists for the KLOW blend, each component's literature must be read separately. These are research-context figures for the species and routes studied:

KPV (10 mg in canonical KLOW vial). In the key murine colitis study, KPV was administered at 100 micromolar concentration in drinking water; in vitro effects were observed at nanomolar concentrations in cell culture ^[3]. The PepT1-targeted nanoparticle formulations used peptide doses not explicitly stated in the abstracts ^[8][12]. KPV is a tripeptide (MW 342.44 Da) and clears rapidly; no human PK study has been published.

GHK-Cu (50 mg in canonical KLOW vial). In vitro gene-expression effects were observed at 1–10 nanomolar concentrations ^[5]. Topical cosmetic formulations in human studies used standard dermatological vehicle concentrations; the Pickart review cites placebo-controlled topical data without specifying systemic plasma concentrations ^[4]. No systemic human PK study for GHK-Cu has been published. Plasma endogenous GHK levels are in the nanomolar range (approximately 200 ng/mL in young adults) ^[4].

BPC-157 (10 mg in canonical KLOW vial). Rodent studies used doses of 10 micrograms, 10 nanograms, and 10 picograms per rat via intraperitoneal injection, once daily ^[2]. The 2025 human IV pilot administered 10 mg on day 1 and 20 mg on day 2 in 250 cc saline via a 1-hour infusion to two adults, with no adverse events ^[6]. BPC-157 has a short elimination half-life (under approximately 30 minutes in formal PK data). FDA placed BPC-157 in category 2 of the 503A bulk-substances review.

TB-500 (10 mg in canonical KLOW vial). Most rodent wound models used topical or intraperitoneal thymosin beta-4; the pivotal Malinda 1999 wound study noted activity at as little as 10 picograms in migration assays ^[1]. As little as 10 pg stimulated keratinocyte migration 2–3-fold in vitro. The TB-500 fragment's PK parameters have not been formally characterized in published human studies. Full-length thymosin beta-4 (from which TB-500 derives) has appeared in early-phase trials; those PK data do not automatically transfer to the fragment.

KLOW peptide dosage and frequency: the pharmacokinetic mismatch

The four KLOW peptides have markedly different molecular weights (342 Da for KPV / 403 Da for GHK-Cu / 1,420 Da for BPC-157 / 889 Da for TB-500), different charges, different receptor targets, and different reported half-lives. A single co-formulated dose cannot put all four at matched plasma exposures simultaneously.

The two tripeptides — KPV and GHK-Cu — are small, hydrophilic, and expected to clear faster than the 15-amino-acid BPC-157. The TB-500 heptapeptide fragment behaves differently from native thymosin beta-4, whose PK profile has been characterized in early-phase trials. BPC-157 has a short elimination half-life (under ~30 minutes in the formal PK publication).

This mismatch is a structural feature of the co-formulated vial, not a failure of formulation: the rationale is not that all four are present simultaneously at matched levels, but that each contributes its own kinetic profile across a dosing interval. Whether that produces meaningful additive effects or an effective dose of any one component has never been tested. All synergy claims from the KLOW blend literature are mechanistic extrapolations, not PK-confirmed.

Routes studied in the component literature

The four components have been studied via different routes in different contexts:

• Subcutaneous injection — the standard research-handling route for reconstituted peptide blends.
• Intraperitoneal injection — used for BPC-157 rodent studies (Staresinic 2003 ^[2]) and thymosin beta-4 wound models (Malinda 1999 ^[1]).
• Topical — GHK-Cu in skin and wound-healing studies ^[4]; thymosin beta-4 in the Malinda 1999 wound model ^[1].
• Oral / targeted-delivery — KPV in drinking-water colitis models ^[3] and KPV nanoparticle formulations ^[8][12].
• Intravenous infusion — the 2025 BPC-157 human safety pilot administered IV infusion over 1 hour ^[6].

The KLOW vial as a research co-formulation is most commonly handled via subcutaneous reconstitution. The different components' absorption, distribution, and metabolism via this shared route have not been characterized for the combination.